growth acceler
reiter outperform rate increas target price
gain greater comfort execut key product launch forecast
acceler organ growth driven
hygien platform asia uptak new bioag corn product
market share gain bioenergi believ nvz valuat re-rat toward
histor high price-to-earnings market gain comfort acceler growth
household hygien roll-out novozym launch new
rang hygien enzym ariel brand product roll
asia europ us thereaft ariel
lead global automat laundri deterg market share
estim global roll-out arial alon support dkr annual revenu
household growth option
volumes/acr doubl origin stack
new biolog product estim combin addit yield
last year take sell price
tripl corn biolog sale
doubl
oil price driven share gain base histor relationship
oil price market share organ growth expect energi sustain
high singl digit growth household return mid-
singl digit growth typic month lag oil move higher
sept expect novozym reconfirm guidanc
organ return growth near term long term
valuat valu novozym averag pe
ev/ebitda dcf wacc greatest risk thesi
fall oil price lead market share loss bioenergi
valuat metric
price month
price rel chart measur perform
omxc close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novozym a/ denmark-bas biotechnolog compani
engag product sale industri enzym
busi consist two segment enzym busi segment
price sep rate outperform target price analyst mathew hampshire-waugh
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
return peak oil would gener organ growth
could justifi novozym rerat toward histor pe premium
return trough oil would gener organ growth could
justifi novozym derat toward low end histor pe
trade
price rel chart measur perform omxc
close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
figur organ growth bridg run rate ex energi organ growth
bioenergi
one-off
figur organ growth bridg mid-term base oil product launch
yeast
previous demonstr organ growth expect biggest
driver valuat novozym price oil
estim organ growth acceler exclud
bioenergi support roll-out hygien corn product
alongsid oil price driven share gain bioenergi
beyond estim organ growth acceler per annum
support growth core busi support oil price share gain
household contribut new product launch
believ market gain comfort return high singl digit growth
novozym re-rat histor price-to-earnings valuat premium price-to-earnings
figur show expect organ growth
headlin organ growth premis upon
organ growth exclud larg organ growth
contribut energi total organ growth includ energi
bioenergi estim current oil price support organ growth
bioenergi given difficult compar add
household one-off includ neg one household
exclud add group growth
corn product bioag drive addit
revenu yoy contribut group
roll-out household hygein product asia add
household growth group
share gain household estim household start see
chemic enzym switch oil price expect higher
month
run detail follow section report
figur estim organ revenu bridg
novozym launch new rang hygien enzym product
enzym help elimin odour caus bacteria even wash low
temperatur believ rang highli success given
product kind market enabl key claim wash powder
novozym reveal product rolled-out ariel brand wash
powder product launch philippin roll
new rang rest asia follow europ powder product
liquid product novozymes/p target us launch
dose problem top load wash machin overcom
philippin ariel/hygien advertis campaign found youtub
market remov even invis kulob sweat stain mention
market campaign show clearli push ad featur rather
mention new formul believ mean better retent enzym
formul increas chanc laundri deterg
produc follow hygein trend novozym compani
figur show market share brand type region global note
ariel/tid lead global product automat laundri product
figur automat laundri product market region/brand share
base global revenu automot laundri ariel/tid gener
revenu asia europ us row
total autom laundri care market
figur automat laundri product market region/brand usd mn
novozym household busi enzym laundri care impli
revenu novozym occupi market impli
enzym market laundri
figur estim breakdown enzym revenu laundri usd
automat laundri market
laundri
estimate number enzym class
estimate valu laundri
averag formul
divid laundri enzym market automat laundri market impli
enzym final product price given weight averag enzym content
strain per averag global product impli everi ad strain gener final
laundri product sell valu revenu enzym maker
figur estim hygien enzym revenu ariel potenti total automat laundri
revenu ariel usd mn
hygien valu
timelin
revenu total laundri
hygien valu
given novozym hightlight enzym replac
formul believ use final revenu good rule thumb figur
show revenu contribut novozym ad hygien enzym
product rang ariel/tid brand name
philippin rel insignific contribut act first test market
perfect brand roll-out
asia gener revenu per year ariel assum novozym make
impli revenu hygien enzym equat
addit growth household group
europ use math europ powder europ liquid add anoth
revenu household
us/oth add revenu household
cumul contribut ariel roll-out household
revenu believ visibl roll-out next month good base
agre volum offtak us launch still subject perfect formul
broaden analysi blue sky scenario includ whole automat
laundri market take total household
novozym target full opportun product rang
bioag feed divis novozym launch first biolog corn inocul
acceleron sat partner monsanto first product kind
market base bacterium penicillium bilaia act releas
phosphat bound soil plant uptak nutrient first
iter product class improv yield bushel per acr
year novozymes/monsanto launch st stack b-
new biolog enhanc mycorrhiz colon increas root volum
plant improv water/nutri uptak
monsanto year field trial indic dual stack biolog improv yield
averag bushel per acr
enhanc yield dual product sold year increas realiz price
novozymes/monsanto typic farmer take yield benefit
supplier take base current corn price shown tabl
increas averag sell price combin biolog
figur credit suiss estim sell price corn bioag product
benefit farmer
valu share bioag allianc farmer
valu farmer
valu allianc
valu farmer
valu allianc
furthermor novozymes/monsanto expect sell acr worth volum
doubl level combin averag price increas
almost tripl revenu product rang add sale yoy
beyond expect product continu roll across us corn acr
charl martineau pm univers toronto figur credit suiss estim corn bioag product
revenu opportun corn busi
penetr corn acr
organ growth contribut ag feed year
organ growth contribut group year
previous detail link higher oil price market share gain
novozym bioenergi household divis re-acceler growth
bioenergi base oil estim bioenergi sustain mid-high singl digit
organ growth base histor correl oil price higher oil typic mean
novozym win market share sell higher yield enzym ethanol
per bushel corn vs competit forecast division organ growth
household oil household histor sustain organ
growth relationship tend lag oil price month depend
custom switch chemic base ingredi enzym oil/chem becom
expens requir month reformul time happen
custom take view sustain higher chemic price estim
division organ growth contribut
mid-term review underli core opportun exist busi overlay
growth opportun ongoing/new product launch believ spot
oil/corn/soy core novozym busi grow success execut
new product pipelin add anoth growth per annum medium
term summaris growth avenu follow
growth believ underli busi correl commod
price indirect relationship wherebi higher commod price typic
favour novozym market share/pr favour use high yield/high
perform enzym regress base model suggest oil novozym
core grow organ
hygien novozym ramp rang hygien enzym wash powder
acceler first product type market
enabl erad odour caus bacteria degre wash
corn innocul novozym start deliv corn inocul bacteria partner
monsanto sale product ramp
introduct acceleron higher yield stack
probiot novozym develop launch probiot poultri
farm product bacterium grow gastrointestin tract
anim prevent harm bacteria colon gut increas yield
yeast ethanol novozym roll rang high perform yeast
ethanol produc reduc ferment time
palm oil process novozym launch enzym rang
improv yield palm oil process
cellulos add revenu ethanol trial industri plant ramp
oper rate come year howev continu believ industri
becom materi oil price sub given neg irr ex subsidi
yeast
full detail analysi includ re-acceler growth
novozym host sept raleigh us
day focu household bioenergi food beverag overview
innov platform includ hygien emerg market solut veget oil
process grain mill anim health biomass convers water solut
day focu deep dive bioag financi
organ growth ebit margin flat net incom
mid-term return organ growth per annum roic/ebit margin
long term target organ growth driven innov roic/ebit margin
expect financi target chang
return
credit suiss forecast broadli line consensu ebit howev
forecast faster acceler organ growth vs consensu
off-set mute margin accret
expect higher organ growth rate household energi
ag/fe base detail analysi market opportun new product
underli market growth spot oil price
increas novozym target price
round averag pe ev/ebitda peer multipl dcf
flavour fragranc givaudan symris sensient sell tast scent
product similar consum market gener slightli lower organ growth
christian hansen sell cultur probiot consum market
histor gener consist higher growth/return vs novozym
figur target price dkr/sh round
pe valuat appli price-to-earnings multipl novozym ep
price-to-earnings ep take evenli weight averag yield
valuat multipl repres premium basket
peer repres fair valu base rel organ growth perform
view figur
ev/ebitda valuat appli ev/ebitda multipl novozym
ebitda ev/ebitda multipl ebitda
evenli weight averag yield valuat multipl
premium basket peer repres fair valu base rel growth
perform view figur
figur peer price-to-earnings ev/ebitda multipl
re-rat share toward histor averag
expect re-rat share toward
dcf valu novozym dkr base follow assumpt
explicit forecast year ebit growth driven top-line expans
adjust ebit margin flat
period year ebit margin growth
termin period ebit margin growth per annum flex
termin period assumpt margin
ebitda margin yield warrant price sensit
wacc base beta equiti risk premium target gear
nd/ev believ beta appropri given novozym
resili stock european chemic compani grow
earnings/consensu upgrad see resili cycl
share
less increase/add decreas wc
free cash-flow firm fcff
cumul factor period
discount factor start first forecast period
equiti
debt
averag spread risk-fre rate
pre-tax cost debt
averag corpor tax rate compani
post-tax cost debt
number year explicit estim
year start termin period
figur dcf sensit termin period assumpt
warrant price sensit termin
growth rate margin
compani mention price
